Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0311120070480061020
Yonsei Medical Journal
2007 Volume.48 No. 6 p.1020 ~ p.1027
Sulindac Prevents Esophageal Adenocarcinomas Induced by Gastroduodenal Reflux in Rats
Kim Sung-Wook

Jang Suk-Yong
Jung Ki-Hoon
Suh Jeong-Ill
Abstract
Purpose: It is known that cyclooxygenase (COX)-2 expression is increased in Barrett¡¯s esophagus and esophageal adenocarcinomas. We studied COX-2 expression and the effect sulindac has on the genesis of Barrett¡¯s esophagus and adenocarcinoma in rats undergoing esophagogastroduodenal anastomosis (EGDA).

Materials and Methods: Fifty-one rats were divided into a control group (n=27), a 500ppm sulindac-treated group (n=15) and 1000 ppm sulindac-treated group (n=9). Randomly selected rats were killed by diethyl ether inhalation at 20 and 40 weeks after surgery.

Results: At 40 weeks, rats treated with 1000 ppm sulindac showed narrower esophageal diameter and milder inflammation than the control rats. At 40 weeks, the incidence of Barrett¡¯s esophagus was similar between control and sulindac-treated groups, but the incidence of adenocarcinoma was significantly lower in the 1000ppm sulindac-treated group than either the control or 500 ppm sulindac-treated groups. COX-2 was significantly increased in the lower esophagus of control rats killed at 40 weeks. Cyclin D1 expression was negligible in the sulindac- treated group compared with the control group.

Conclusion: We suggest that the chemopreventive effect of sulindac is related to decreased COX-2 and cyclin D1 expression, which may be influenced by reduced inflammation
KEYWORD
Barrett¡¯s esophagus, esophageal adenocarcinoma, COX-2, sulindac
FullTexts / Linksout information
  
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed